Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,265 across all filing types
Latest filing 2021-02-03 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. It is an official notification related to share certificates but not a financial report or earnings release. The document is short (1575 characters) and serves as a regulatory announcement about share certificate status. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance notification that does not fit other specific categories.
2021-02-03 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates and the request for issuance of duplicate certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. It is an announcement related to shareholding records and regulatory compliance, not a financial report or meeting material. The document length is short (1575 characters), and it is a notification to exchanges rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-03 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board of Directors meeting scheduled for February 8, 2021, to consider and approve the unaudited financial results for the quarter ended December 31, 2020. It also mentions the closure of the trading window for insiders. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about a future event (board meeting and financial results approval). The document length is short (1544 characters), and it serves as an announcement rather than a report. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-01-29 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2021 ,inter alia, to consider and approve the Unaudited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board of Directors meeting scheduled for February 8, 2021. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended December 31, 2020. The document also mentions the closure of the trading window for insiders. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement about a future board meeting and the expected approval of quarterly results. The document length is short (1544 characters), and it serves as a notification rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-01-29 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges (BSE and NSE) regarding a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It mentions the enclosure of a certificate from the Registrar and Transfer Agents confirming compliance with a regulatory requirement. The document does not contain any financial data, detailed report, or management discussion. It is primarily a regulatory compliance certificate submission. The document length is only 1518 characters, indicating it is a brief communication rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-01-27 English
We are enclosing herewith Certificate dated January 1, 2021 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming ....
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges (BSE and NSE) dated January 25, 2021. It references a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the company's Registrar and Transfer Agents. The letter requests the exchanges to take the certificate on record. There is no financial data, no detailed report, no management discussion, or earnings information. The document is primarily a compliance certificate submission. The length is only 1518 characters, indicating it is a brief regulatory filing rather than a full report. According to the rules, such compliance certificates and attestation letters fall under Regulatory Filings (RNS).
2021-01-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.